恒瑞医药：子公司帕立骨化醇软胶囊获批上市

Core Viewpoint - Heng Rui Medicine announced that its subsidiary Chengdu Shengdi Pharmaceutical Co., Ltd. received notification from the National Medical Products Administration, approving the market launch of Paricalcitol soft capsules [1] Group 1: Product Details - The drug specifications are 1μg and 2μg, intended for the prevention and treatment of secondary hyperparathyroidism in adults with chronic kidney disease stages 3-4 [1] - Paricalcitol soft capsules have not been previously launched in the domestic market, making the company the first generic drug enterprise in the country to receive approval, which is considered equivalent to passing the consistency evaluation [1] Group 2: Financial and Development Insights - Cumulative research and development investment for this project amounts to approximately 57.94 million yuan [1] - The production and sales of the drug post-approval may be influenced by uncertain factors [1]